A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.

Michael Jefford; Michael Michael; Mark A Rosenthal; Ian D Davis; Michael Green; Bev McClure; Jennifer Smith; Brigid Waite; John Zalcberg

doi:10.1023/B:DRUG.0000011796.20332.a9

A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.

Identifier:nobleid.org/w1/20260515/89CE35AC

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/89CE35AC.svg?ark=w1%2F20260515%2F89CE35AC)](https://nobleid.org/work/w1/20260515/89CE35AC)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.

Identifier:nobleid.org/w1/20260515/89CE35AC

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/89CE35AC.svg?ark=w1%2F20260515%2F89CE35AC)](https://nobleid.org/work/w1/20260515/89CE35AC)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work